|Position||Trades||Duration||Win rate||Win/loss||Avg win||Avg loss||Return|
|Position||Trades||Duration||Win Rate||Win/Loss||Avg Win||Avg Loss||Return|
COMMODITY CHANNEL INDEX
Trading: HOLD @ $3.61
Signal Strength: MEDIUM
Opthea (ASX:OPT) current trading has maintained the Commodity Channel Index to oversold status and signalled the continuation of the bullish trading conditions. Currently, the CCI is 117. The bullish signal has been active for 0 day. During the quarter, the lowest CCI value was 8.
Indicator can be used in isolation or in additional to another technical indicator to confirmation for trading entry. Indicator can be applied to the short/medium term timeframe, but the best results are obtained with larger cyclical swings in-line with the trend direction. This accumulation / distribution oscillator can provide guidance on the money flow direction from the companies recent trading.
The Commodity Channel Index indicator takes a security’s change in price and compares that to its average change in price. CCIs calculation produces positive and negative values that oscillate above and below a Zero Line. Typically a value of 100 is identified as overbought and a reading of -100 is identified as being oversold.
Calculation: 20 Period CCI:
1) CCI = (Typical Price - 20 Period SMA of TP) / (.015 x Mean Deviation);
2) Typical Price (TP) = (High + Low + Close)/3;
PROFILE: Opthea (OPT.AX)
Stock Exchange: ASX
Ticker Codes: | OPT.AX | ASX:OPT |
Opthea Limited develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) C and D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead molecule is OPT-302, a soluble form of VEGFR-3, which is in Phase 1/2A clinical trial for the treatment of back of the eye diseases, such as wet age-related macular degeneration that is the cause of blindness in elderly and diabetic populations. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited is based in South Yarra, Australia.
|MVP Medical Developments||10.28||8.8||674,204||47||BULLISH|
|DOW Downer EDI||7.6||6||10,946,339||91||BULLISH|
|NZK New Zealand King Salmon Investments||2.2||5.3||8,766||-228||BULLISH|
|MNS Milnes Holdings||0.11||4.8||239,846||78||BULLISH|
|HFR Highfield Resources||0.8||4.6||86,664||31||BULLISH|
|SYR Syrah Resources||0.6||3.5||2,137,353||25||BULLISH|